Raphael Pharmaceutical (RAPH) EBT Growth (1y) (2021 - 2026)
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) EBT Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 76.53% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -522.15% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 8.48% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 0.60% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 88.92% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 6.23% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 530.43% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -82.20% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | 36.83% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36.83% |
| Jun 30, 2025 | -26.51% |
| Dec 31, 2024 | -394.03% |
| Sep 30, 2024 | 56.24% |
| Jun 30, 2024 | 40.57% |
| Mar 31, 2024 | -112.02% |
| Dec 31, 2023 | 112.14% |
| Sep 30, 2023 | 48.88% |
| Jun 30, 2023 | 31.54% |
| Mar 31, 2023 | -47.43% |
| Dec 31, 2022 | -92.33% |
| Sep 30, 2022 | -241.15% |
| Jun 30, 2022 | -58.96% |
| Mar 31, 2022 | 30.56% |
| Dec 31, 2021 | -152.86% |